Skip to main content
. 2023 Jun 13;22:138. doi: 10.1186/s12933-023-01864-x

Table 2.

Baseline characteristics of the Survivors and Non-survivors groups

Categories Overall (N = 773) Survivor (N = 594) Non-survivor (N = 139) P-value
Age (years) 69 (58–79) 68.5 (57–78) 70 (59–81) 0.179
Height (cm) 168 (160–178) 168 (163–178) 168 (160–175) 0.116
Weight (kg) 79.3 (67.8–93.4) 79.3 (68-93.9) 78.4 (67.0-92.2) 0.582
BMI 27.5 (24.0-32.2) 27.4 (24.1–32.0) 27.7 (23.4–32.6) 0.997
Sex: male 409 (55.8) 342 67 0.028
SOFA 4 (2–6) 4 (2–6) 5 (3–8) < 0.001
APS III 41 (30–57) 40 (29–55) 47 (35–65) < 0.001
SAPS II 35 (28–34) 34 (27–43) 41 (33–49) < 0.001
OASIS 33 (27–39) 32 (27–38) 36 (30–43) < 0.001
GCS 14 (11–15) 14 (11–15) 15 (10–15) 0.196
Commorbidities
Heart failure 207 (28.2) 164 43 0.247
Arterial fibrillation 293 (40.0) 229 64 0.064
Diabetes 268 (36.6) 211 57 0.134
Paraplegia 323 (44.1) 265 58 0.301
Renal disease 127 (17.3) 106 21 0.263
Sepsis 112 (15.3) 77 35 < 0.001
CCI 6 (5–8) 6 (4–8) 7 (5–9) 0.021
Laboratory tests
WBC, K/uL 9.9 (7.6–13.1) 9.6 (7.4–12.6) 11.7 (8.4–15.8) < 0.001
RBC, m/uL 3.7 (3.2–4.3) 3.8 (3.2–4.3) 3.7 (3.0-4.2) 0.032
Platelet, K/uL 219 (166–289) 225 (169–298) 207 (142–263) 0.001
Hemoglobin, g/dL 11.1 (9.4–12.8) 11.1 (9.5–12.9) 10.8 (9.0-12.5) 0.054
Sodium, mEq/L 140 (137–143) 140 (137–142) 140 (137–143) 0.675
Serum creatinine 0.9 (0.7–1.3) 0.9 (0.7–1.3) 1.1 (0.7–1.4) 0.018
TG, mg/d 114 (84–167) 114 (85–165) 117 (80–168) 0.812
FBG, mg/dL 125 (104–153) 120 (102–149) 137 (117–173) < 0.001
TyG index 8.90 (8.53–9.34) 8.88 (8.51–9.29) 9.05 (8.64–9.54) 0.005
IV-tPA 129 (17.6) 108 (18.1) 21 (15.2) 0.392
Mechanical thrombectomy 74 (10.1) 59 (9.9) 15 (10.8) 0.762

Abbreviation: TyG index, triglyceride glucose index; BMI, body mass index; SOFA, sequential organ failure assessment; CCI, Charlson comorbidity index; APSIII, acute physiology score III; SAPSII, simplifed acute physiological score II; OASIS, oxford acute severity of illness score; GCS, Glasgow coma scale; WBC, white blood cell; RBC, red blood cell; TG, triglyceride; FBG, fasting blood glucose; IV-tPA, intravenous tissue plasminogen activator